Related Experiment Videos
Nasal CPAP in cardiac failure: case not proven
1Department of Medicine, Aintree Hospital NHS Trust, University of Liverpool, U.K.
Sleep
|December 1, 1996
Summary
Cheyne-Stokes Respiration (CSR) is common in heart failure patients and predicts mortality. While nasal CPAP may improve some aspects of heart failure, its long-term benefits and role in treatment remain uncertain.
Area of Science:
- Cardiology
- Pulmonology
- Sleep Medicine
Background:
- Cheyne-Stokes Respiration (CSR) is prevalent in congestive cardiac failure (CCF) patients (≥45%) and is a mortality predictor.
- Nasal continuous positive airway pressure (CPAP) can reduce breathing work in CCF short-term and may improve cardiac function and sleep quality with chronic use.
Purpose of the Study:
- To evaluate the established role of nasal CPAP in the maintenance treatment of congestive cardiac failure (CCF).
Main Methods:
- Review of existing studies on nasal CPAP in CCF patients, including those with atrial fibrillation.
- Assessment of short-term and longer-term (up to 1 month) treatment periods.
- Consideration of factors like CPAP acclimatization and patient selection.
Main Results:
- Some studies report limited benefits of nasal CPAP in patients with minimal sleep-disordered breathing.
- CPAP has been shown to depress left ventricular ejection fraction in atrial fibrillation patients, particularly with low systemic vascular resistance.
- Oxygen or ACE inhibitors may improve sleep quality, but chronic cardiac function benefits are not well-documented.
Conclusions:
- The role of nasal CPAP in the maintenance treatment of CCF is not yet established.
- Further research is needed to clarify the benefits and optimal use of CPAP in CCF management.
- Current evidence is based on small, short-term studies, lacking mortality benefit data.